BRD2 and breast carcinoma: found that 57% of premenopausal patients with early breast cancer suffered from chemotherapy-induced ovarian failure (CIOF) after taxanes monotherapy, defined as FSH>12.4 IU/L, E2<52.2 ng/L, amenorrhea, and AMH level <0.22 ng/mL after treatment.